Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human M9140 study in advanced colorectal cancer
jRCT2031220313Phase 1Active, not recruiting
- Sponsor
- Merck KGaA
- Start
- Sep 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of precemtabart tocentecan in colorectal cancer (CRC) (5 arms), sponsored by Merck KGaA. Primary endpoints: Number of participants with dose-limiting toxicities, Recommended dose for expansion of M9140 and 3 more. Started Sep 2022; status: active, not recruiting.
02
Drugs
precemtabart tocentecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031220313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220313.